Ifigenia Vasiliadou, Derek Grose, Christina Wilson, Alekh Thapa, Olly Donnelly, Elsa Lee, Isla Leslie, Mahwish Karim, Andrew Hartley, Sarah Partridge, Katharine Medlow, James De Boisanger, Robert Metcalf, Andrew Williamson, Anoop Haridass, David Noble, Karen Mactier, Harriet Walter, Ning Ma, Emma De Winton, Jennifer Cohen, Lindsay Rayner, Konstantinos Geropantas, Petra Jankowska, Jessica Mason, Rafael Moleron, Kirsten Laws, Danny Ulahannan, Chandran Nallathambi, Andriana Michaelidou, Susanna Nallamilli, Sherif Raouf, Kieran Palmer, Maya Bienz, Tracy Karet, Saira Khalique, Claire Paterson, Kevin Harrington, Shreerang Bhide, Anthony Kong
Pembrolizumab has received approval in the UK as first-line monotherapy for recurrent and/or metastatic HNSCC (R/M HNSCC) following the results of the KEYNOTE-048 trial, which demonstrated a longer overall survival (OS) in comparison to the EXTREME chemotherapy regimen in patients with a combined positive score (CPS) ≥1. In this article, we provide retrospective real-world data on the role of pembrolizumab monotherapy as first-line systemic therapy for HNSCC across 18 centers in the UK from March 20, 2020 to May 31, 2021...
April 29, 2024: International Journal of Cancer. Journal International du Cancer